

Supplemental Digital Content 3. Tables and figures - Baseline characteristics and immunogenicity data for participants in groups receiving MenABCWY in the primary or extension study

Table S3_1. Demographic and baseline characteristics for participants in groups receiving MenABCWY in the primary or extension study (enrolled set)

	ABCWY/ ABCWY	ABCWY/ placebo	4CMenB/ ABCWY	ACWY/ ABCWY	ACWY/ placebo
N	26	25	11	21	19
Age ± SD, years	18.8±5.19	17.1±4.31	20.9±3.99	16.8±4.65	17.6±5.19
Female, n (%)	8 (31%)	13 (52%)	2 (18%)	12 (57%)	11 (58%)
Geographic ancestry, n (%)					
Asian	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)
Black/African American	3 (12%)	1 (4%)	0 (0%)	0 (0%)	1 (5%)
White	22 (85%)	22 (88%)	11 (100%)	21 (100%)	18 (95%)
Other	1 (4%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)
Height ± SD, cm	170.8±9.85	167.6±10.71	178.4±8.76	164.8±8.35	165.1±9.45
Weight ± SD, kg	72.4±19.42	67.4±21.1	76.6±12.24	65.6±15.34	74.8±28.61
Body mass index± SD, kg/m ²	24.8±6.23	23.9±7.05	24.2±3.83	24±4.45	26.9±8.05


N, number of participants in each group; n (%), number (percentage) of participants in each category; SD, standard deviation.

Table S3_2. GMTs and GMRs from extension baseline to 1 month post-booster against serogroups A, C, W and Y (Day 30 full analysis set for immunogenicity)

	ABCWY/ABCWY		ABCWY/placebo		4CMenB/ABCWY		ACWY/ABCWY		ACWY/placebo	
	N	GMT/GMR (95%CI)	N	GMT/GMR (95%CI)	N	GMT/GMR (95%CI)	N	GMT/GMR (95%CI)	N	GMT/GMR
Serogroup A										
Extension baseline GMT	25	3.41 (1.87–6.22)	25	2.92 (1.59–5.36)	11	2.26 (0.96–5.31)	19	6.62 (2.85–15)	18	5.02 (2.06–12)
1M post-booster GMT	25	259 (174–383)	25	4.28 (2.03–9.03)	11	438 (287–670)	19	138 (84–229)	18	4.91 (2.00–12)
1M post-booster GMR	25	76 (40-144)	25	1.47 (0.83-2.59)	11	194 (95-397)	19	21 (9.33-47)	18	0.98 (0.79-1.21)
Serogroup C										
Extension baseline GMT	20	23 (9.45–57)	23	16 (7.06–36)	7	5.45 (2.41–12)	21	7.75 (4.19–14)	17	17 (6.60–44)
1M post-booster GMT	21	660 (401–1084)	24	17 (7.60–38)	7	292 (75–1142)	21	338 (205–558)	18	20 (7.20–56)
1M post-booster GMR	20	29 (14-62)	23	1.06 (0.89-1.28)	7	54 (14-209)	21	44 (22-87)	17	1.27 (0.73-2.21)
Serogroup W										
Extension baseline GMT	20	34 (20–59)	24	33 (17–65)	11	25 (7.98–79)	18	28 (12–66)	15	9.42 (3.03–29)
1M post-booster GMT	20	792 (516–1216)	24	34 (16–71)	11	392 (252–610))	19	629 (384–1032)	16	16 (4.87–53)
1M post-booster GMR	20	23 (12-46)	24	1.04 (0.82-1.31)	11	16 (6.19-39)	18	23 (9.49-54)	15	1.64 (0.72-3.74)
Serogroup Y										
Extension baseline GMT	25	10 (4.89–21)	25	15 (5.50–43)	11	2.40 (1.05–5.47)	21	6.43 (2.86–14)	18	5.32 (1.81–16)
1M post-booster GMT	25	464 (294–734)	25	16 (5.65–48)	11	48 (14–157)	21	658 (431–1003)	18	6.36 (1.91–21)
1M post-booster GMR	25	45 (22-93)	25	1.06 (0.68-1.67)	11	20 (5.10-78)	21	102 (41-256)	18	1.20 (0.51-2.82)

GMT, geometric mean titer; GMR, geometric mean ratio; N, number of participants with available serum samples in each group; CI, confidence interval; M, month.

Figure S3_3. hSBA geometric mean titres for serogroups A, C, W and Y (Day 365 full analysis set for persistence)



hSBA, bactericidal assay with human complement; M, month.

Note: Error bars depict 95% confidence intervals.